- >
原料配方
MenaquinGold®
MenaquinGold®
The future is golden
Introducing MenaquinGold®, our natural vitamin K2 produced utilizing a patented chickpea fermentation process in our soy-free, non-GMO manufacturing facilities. With an FDA issued GRAS ‘No objection letter’ and supported by scientific research and clinical trials, MenaquinGold® is a key ingredient to building a healthier future.
Good for more than you think possible
Vitamin K2 has been associated with health benefits within several areas. The indications with the most substantiated evidence are bone health1 and heart health,2,3,4 but emerging science indicates promising results related to sports performance and nerve health.5,6,7
Binds calcium
Vitamin K2-7 is observed to activate the bone protein osteocalcin, which is essential to bind calcium effectively to the bone matrix.1
Heart health benefits
Vitamin K2-7 has been associated with heart health benefits.9,10,2,3
Nerve and sports health benefits
Proprietary research on MenaquinGold® suggests vitamin K2-7 may provide health benefits in relation to nerve health and sports health.
What is vitamin K2?
Vitamin K is a collective term for like, fat-soluble compounds. There are two kinds of vitamin K: vitamin K1 (phylloquinone or phytonadione) and vitamin K2 (menaquinone). As vitamin K2 can differ in number side chains of the molecule you might come across names as vitamin K2-4 (four side groups), also called MK-4, (for menaquinone K-4) or K2-7 (seven side groups) also called MK-7.
Fermenting…chickpeas!
Manufacturing MenaquinGold® with zero soy
We’ve always believed it’s the small things that can make a big difference, and chickpeas are a prime example! We know from experience that allergies and purity concerns are top of mind for consumers, so ensuring our MenaquinGold® production facilities are soy-free has been of utmost importance.
Our process of submerged fermentation with a Bacillus liciniformis strain is patented and thanks to our proprietary extraction method, we have good stability records by preventing the accumulation of metabolites that affect the long-term stability of vitamin K2-7.
MenaquinGold® is manufactured in-house at our GMP-certified plant near Mumbai, India. The world-class facility is equipped with the highest quality technologies and equipment, as you would expect from Novozymes, the world’s leading enzyme producer. The facility is cGMP, HACCP, and ISO 22000 certified.
Classified as GRAS with ‘No objection' response from the FDA
Novozymes OneHealth is proud to announce that the FDA has issued a GRAS (Generally Recognized As Safe) 'No objection' letter for MenaquinGold®. This means the FDA has no objection to the GRAS self-affirmation notification our scientists established and submitted. Our FDA GRAS status is for children (GRAS Notification GRN000887).
Applications flourish with MenaquinGold® with flexible formulations
MenaquinGold® can be formulated as a stand-alone input or in combination with other functional ingredients. Our team can assist you to meet the growing demand for products fortified with vitamin K2-7.
MenaquinGold® is available across multiple product grades and concentrations – so you can add it to the dosage form of your choice. Our powder grade is suitable for most dry blends including capsules and tablets without alkaline or aggressive components. Our Extended Stability option is ideal for highly alkaline products such as calcium mineral complexes, and our water-soluble product is perfect for applications such as sachets, beverage powder blends, and liquids. Granules are also available for tablet and capsule applications. Finally, we have MenaquinGold® in an MCT oil form.
Discover a world of K2 science and applications
Discover the untapped potential of a novel vitamin for multiple lifestyle health challenges
Science is pushing the boundaries of what’s possible in treating health conditions, as well as in preventative health care. A key market booming from this combination of scientific innovation and consumer activism, is nutraceuticals.
The number of Americans who use dietary supplements is growing across age groups and at present, research suggests over 70% of Americans believe dietary supplements play an important part in lifestyle change.
One nutraceutical that increasingly gets attention is Vitamin K2.
We keep our finger on the market’s pulse and we’ve invested in our own research. Let us share our findings with you. You'll be ahead of the competition and one step closer to meeting the needs of consumers.
Van Summeren, M., Braam, L., Lilien, M., Schurgers, L., Kuis, W., & Vermeer, C. (2009). The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children. British Journal of Nutrition, 102(8), 1171-1178. doi:10.1017/S0007114509382100
Geleijnse, J. M., Vermeer, C., Grobbee, D. E., Schurgers, L. J., Knapen, M. H., van der Meer, I. M., Hofman, A., & Witteman, J. C. (2004). Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. The Journal of nutrition, 134(11), 3100–3105. https://doi.org/10.1093/jn/134.11.3100
Gast, G. C., de Roos, N. M., Sluijs, I., Bots, M. L., Beulens, J. W., Geleijnse, J. M., Witteman, J. C., Grobbee, D. E., Peeters, P. H., & van der Schouw, Y. T. (2009). A high menaquinone intake reduces the incidence of coronary heart disease. Nutrition, metabolism, and cardiovascular diseases: NMCD, 19(7), 504–510. https://doi.org/10.1016/j.numecd.2008.10.004
Mehta DS, Vaidya RA, Dound YA et al. Therapeutic Activity and Safety of Vitamin K2-7 in Muscle Cramps: An Interventional Case- Series. The Indian Practitioner 2010; May: 287-291.
Kulkarni VK, Upase DU, Dound YA et al. The effect of vitamin K2-7 in peripheral neuropathy due to vitamin B12 deficiency and diabetes mellitus: A Preliminary Study, The Indian Practitioner 2013; 66:625-629
Choi, H. J., Yu, J., Choi, H., An, J. H., Kim, S. W., Park, K. S., Jang, H. C., Kim, S. Y., & Shin, C. S. (2011). Vitamin K2 supplementation improves insulin sensitivity via osteocalcin metabolism: a placebo-controlled trial. Diabetes care, 34(9), e147. https://doi.org/10.2337/dc11-0551
Beulens, J. W., van der A, D. L., Grobbee, D. E., Sluijs, I., Spijkerman, A. M., & van der Schouw, Y. T. (2010). Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes. Diabetes care, 33(8), 1699–1705. https://doi.org/10.2337/dc09-2302
Schurgers, L. J., Teunissen, K. J., Hamulyák, K., Knapen, M. H., Vik, H., & Vermeer, C. (2007). Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood, 109(8), 3279–3283. https://doi.org/10.1182/blood-2006-08-040709
Van Summeren, M., Braam, L., Lilien, M., Schurgers, L., Kuis, W., & Vermeer, C. (2009). The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children. British Journal of Nutrition, 102(8), 1171-1178. doi:10.1017/S0007114509382100
Kaneki, M., Hodges, S. J., Hosoi, T., Fujiwara, S., Lyons, A., Crean, S. J., Ishida, N., Nakagawa, M., Takechi, M., Sano, Y., Mizuno, Y., Hoshino, S., Miyao, M., Inoue, S., Horiki, K., Shiraki, M., Ouchi, Y., & Orimo, H. (2001). Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk. Nutrition (Burbank, Los Angeles County, Calif.), 17(4), 315–321. https://doi.org/10.1016/s0899-9007(00)00554-2
Geleijnse, J. M., Vermeer, C., Grobbee, D. E., Schurgers, L. J., Knapen, M. H., van der Meer, I. M., Hofman, A., & Witteman, J. C. (2004). Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. The Journal of nutrition, 134(11), 3100–3105. https://doi.org/10.1093/jn/134.11.3100
Gast, G. C., de Roos, N. M., Sluijs, I., Bots, M. L., Beulens, J. W., Geleijnse, J. M., Witteman, J. C., Grobbee, D. E., Peeters, P. H., & van der Schouw, Y. T. (2009). A high menaquinone intake reduces the incidence of coronary heart disease. Nutrition, metabolism, and cardiovascular diseases: NMCD, 19(7), 504–510. https://doi.org/10.1016/j.numecd.2008.10.004
BCG commissioned report
BCG commissioned report